epirubicin hydrochloride 10mg/ 5ml injection vial
novotech australia pty ltd - epirubicin hydrochloride -
epirubicin alphapharm epirubicin hydrochloride 100 mg/50 ml concentrated injection vial
alphapharm pty ltd - epirubicin hydrochloride -
epirubicin alphapharm epirubicin hydrochloride 200 mg/100 ml concentrated injection vial
alphapharm pty ltd - epirubicin hydrochloride -
epirubicin alphapharm epirubicin hydrochloride 20 mg/10 ml concentrated injection vial
alphapharm pty ltd - epirubicin hydrochloride -
epirubicin alphapharm epirubicin hydrochloride 50mg/25ml concentrated injection vial
alphapharm pty ltd - epirubicin hydrochloride -
dbl epirubicin hydrochloride injection epirubicin hydrochloride 200mg/100ml injection vial
pfizer australia pty ltd - epirubicin hydrochloride -
dbl epirubicin hydrochloride injection epirubicin hydrochloride 100mg/50ml injection vial
pfizer australia pty ltd - epirubicin hydrochloride -
epirubicin hydrochloride 2 mg/ml solution for injection or infusion
accord healthcare ireland ltd. - epirubicin hydrochloride - solution for injection/infusion - 2 milligram(s)/millilitre - anthracyclines and related substances; epirubicin
epirubicin hydrochloride 2 mg/ml solution for injection or infusion
accord healthcare limited - epirubicin hydrochloride - solution for injection - 2 milligram(s)/millilitre - anthracyclines and related substances; epirubicin
dbl™ epirubicin hydrochloride
pfizer new zealand limited - epirubicin hydrochloride 2 mg/ml; - solution for injection - 2 mg/ml - active: epirubicin hydrochloride 2 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - epirubicin hydrochloride has produced responses in a wide spectrum of neoplastic diseases, and is indicated for the treatment of: · breast cancer, · gastric cancer, · ovarian cancer, · small cell lung cancer, · lymphoma (non-hodgkin's lymphoma), · advanced/metastatic soft tissue sarcoma, and · superficial bladder cancer (tis; ta). in bladder cancer, epirubicin hydrochloride is also indicated in the prophylaxis of recurrence after transurethral resection of stage t1 papillary cancers and stage ta multifocal papillary cancers (grade 2 and 3). epirubicin has also shown antitumour activity in the following tumours: · carcinoma of the oesophagus · primary hepatocellular carcinoma · pancreatic carcinoma · carcinoma of the head and neck · acute leukaemias and multiple myeloma